Spero Therapeutics (SPRO) Revenue & Revenue Breakdown
Spero Therapeutics Revenue Highlights
Latest Revenue (Y)
$96.73M
Latest Revenue (Q)
$13.47M
Spero Therapeutics Revenue by Period
Spero Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $96.73M | 99.13% |
| 2022-12-31 | $48.58M | 166.10% |
| 2021-12-31 | $18.26M | 95.67% |
| 2020-12-31 | $9.33M | 96.75% |
| 2019-12-31 | $4.74M | 19.57% |
| 2018-12-31 | $3.97M | 100.40% |
| 2017-12-31 | $1.98M | 490.75% |
| 2016-12-31 | $335.00K | 100.00% |
| 2015-12-31 | - | - |
Spero Therapeutics generated $96.73M in revenue during NA 2023, up 99.13% compared to the previous quarter, and up 2439.11% compared to the same period a year ago.
Spero Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $13.47M | 123.85% |
| 2024-06-30 | $6.02M | 43.13% |
| 2024-03-31 | $4.20M | -94.15% |
| 2023-12-31 | $71.83M | 181.97% |
| 2023-09-30 | $25.47M | 3132.61% |
| 2023-06-30 | $788.00K | 6.49% |
| 2023-03-31 | $740.00K | -98.40% |
| 2022-12-31 | $46.30M | 4179.26% |
| 2022-09-30 | $1.08M | 20.76% |
| 2022-06-30 | $896.00K | 262.75% |
| 2022-03-31 | $247.00K | -91.00% |
| 2021-12-31 | $2.74M | -10.44% |
| 2021-09-30 | $3.06M | -40.48% |
| 2021-06-30 | $5.15M | -29.48% |
| 2021-03-31 | $7.30M | 282.80% |
| 2020-12-31 | $1.91M | -52.27% |
| 2020-09-30 | $4.00M | 131.33% |
| 2020-06-30 | $1.73M | 921.89% |
| 2020-03-31 | $169.00K | -75.72% |
| 2019-12-31 | $696.00K | 304.65% |
| 2019-09-30 | $172.00K | -92.02% |
| 2019-06-30 | $2.16M | -43.37% |
| 2019-03-31 | $3.81M | 125.00% |
| 2018-12-31 | $1.69M | 157.14% |
| 2018-09-30 | $658.00K | 42.12% |
| 2018-06-30 | $463.00K | -59.84% |
| 2018-03-31 | $1.15M | 16.11% |
| 2017-12-31 | $993.00K | 66.33% |
| 2017-09-30 | $597.00K | 139.76% |
| 2017-06-30 | $249.00K | 77.86% |
| 2017-03-31 | $140.00K | -58.21% |
| 2016-12-31 | $335.00K | 100.00% |
| 2016-09-30 | - | - |
Spero Therapeutics generated $13.47M in revenue during Q3 2024, up 123.85% compared to the previous quarter, and up 1709.26% compared to the same period a year ago.